XORTX reveals positive results for Phase 2 trial of TMX-049
Category: #health  By Pankaj Singh  Date: 2019-09-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

XORTX reveals positive results for Phase 2 trial of TMX-049

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing on developing new drugs by means for novel clinical trials.

XORTX Therapeutics Inc., a biopharmaceutical firm that develops novel therapies to treat advanced kidney disease, recently shared promising results from the U.S. Placebo-Controlled, Randomized, Multicenter, Double-Blind, Phase 2 study to assess tolerability, safety and renal effects of TMX-049 in patients suffering from type 2 diabetic nephropathy.

According to reliable sources, the study intended to test if the inhibition of XO using the drug over a 12-week treatment program would offer an effective and safe therapeutic approach to reduce albuminuria and would decrease uric acid levels.

Commenting on the move, Dr. Allen Davidoff, President and CEO, XORTX Inc., said that the company feels TMX-049 is one of the best next-gen candidate xanthine oxidase inhibitors with a suitable combination of potent uric acid lowering ability and solid clinical safety record.

Moreover, the prospect of co-developing the drug for type 2 diabetic nephropathy alongside Teijin, while providing such significant results, significantly raise the probability of developing an advanced and novel drug to reverse and slow the progression of kidney disease in type 2 diabetic nephropathy patients.

However, earlier this year the company had acknowledged Dr. Petter Bjornstad and TODAY study team’s finding and study on youths going through Type 2 Diabetes (“T2D”). The findings revealed that high uric acid levels were normal in young subjects with T2DN (nephropathy) and that high SUA levels (serum uric acid) was an autonomous risk factor for development of kidney disease in this new and vulnerable group.

Additionally, the biopharma had highlighted an impactful finding by Pilemann-Lyberg et al. Reports cite that the results of this study of subjects with type 1 diabetic nephropathy progresses the crucial mass of seminal studies which reveal the detrimental effects of blood UA (uric acid) levels in the upper range of higher or normal patients suffering from diabetes.

Source Credit: http://www.xortx.com/2019/09/19/xortx-announces-positive-phase-2-results-in-type-2-diabetic-nephropathy-t2dn/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...